If you are wondering whether Omnicell at around US$46 is a bargain or a value trap, this article will walk you through what the current price might be implying.
The stock has had a mixed run, with a 7.8% decline over the last week, a 2.0% gain over the past month, and returns of 2.0% year to date and 5.0% over the last year. It is still sitting well below its 3 year and 5 year levels, with declines of 21.0% and 65.2% over those periods.
Recent coverage around Omnicell has focused on its role as a healthcare technology provider and on how the market is reassessing risk and expectations after a long period of weaker share price performance. This backdrop helps explain why shorter term moves can look quite different from the longer term…
